Improved prenatal investigation for congenital malformations and chromosomal disorders. Advantages and disadvantages of screening and diagnosis;Bedre prænatale undersøgelsesmuligheder for medfødte misdannelser og kromosomsygdomme: Fordele og ulemper ved screening og diagnostik

Ugeskrift for Laeger

Volumn 158, Issue 9, 1996, Pages 1201-1207

  Nørgaard Pedersen, Bent ^a   Larsen, Severin Olesen ^b   Larsen, Jørgen Falck ^b  

^a Klinisk Biokemisk Afdeling

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME ABERRATION; CHROMOSOME DISORDER; CONGENITAL MALFORMATION; DENMARK; FEMALE; GENETIC COUNSELING; GENETICS; HUMAN; MASS SCREENING; METHODOLOGY; PREGNANCY; PRENATAL DIAGNOSIS; REVIEW; STANDARD;

ABNORMALITIES; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; DENMARK; FEMALE; GENETIC COUNSELING; HUMANS; MASS SCREENING; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 0030602443     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Prænatale undersøgelser i Danmark. København: Cytogenetisk Laboratorium: 1992:1-56.
2. Tabor A, Philip J, Madsen M, Bang J, Obel EB, Nørgaard-Pedersen B. Randomised controlled trial of amniocentesis in 4606 low-risk women. Lancet 1986; I:1287-93.
3. Rhoads G, Jackson LG, Schlesselman SE, De La Cruz FF, Desniek RJ, Golbus MS et al. The safety and efficacy of chorionic villus sampling for earlv prenatal diagnosis of cytogenetic abnormalities. N Engl J Med 1989; 320:609-17.
4. Canadian Collaborative CVS-Amniocentesis Clinical Trial Group. Multicentre randomised clinical trial of chorion villus sampling and amniocentesis. First report Lancet 1989; I:1-6.
5. MCR Working Party on the Evaluation of Chorion Villus Sampling. Medical Research Council European Trial of Chorion Villus Sampling. Lancet 1991; 337:1491-9.
6. Lillford RJ. The rise and fall of chorionic villus sampling. BMJ 1991; 303: 936-7.
7. Smidt-Jensen SL, Permia M, Philip J, Lundsteen C, Gruning K. Randomiseret sammenligning af transabdominal transcervikal chorion villus biopsi og amniocentese. Ugeskr Læger 1993; 155: 1446-56.
8. Bryndorf T, Christensen B, Philip J, Hansen W, Yokobata K, Bui N et al. New rapid test for prenatal detection of trisomy 21 (Down's syndrome): preliminary report BMJ 1992; 304:1536-9.
9. Jørgensen FS, Bang J, Lind A-M. Christensen B, Lundsteen C, Philip J. Genetic amniocentesis at 7-14 weeks of gestation. Prenat Diagn 1992; 12:277-83.
10. Sundberg K, Smidt-Jensen S, Lundsteen C, Agerbæk K, Philip J. Filtration and recirculation of early amniotic fluid. Evaluation of cell cultures from 100 diagnostic cases. Prenat Diagn 1993; 13:1101-10.
11. Nørgaard-Pedersen B, Bagger PV, Bang J, Fischer-Rasmussen W, Gad C, Hasch E et at. Serum-alfa-føtoprotein-screening for medfødte misdannelser i 16.-18. graviditetsuge. Ugeskr Læger 1984; 146:3253-9.
12. Arends J, Elleman-Jensen P, Etverdal S, Goldstein H, Jensen NM, Larsen SO et al. Analyse af de økonomiske konsekvenser af S-AFP-screening og ultralydscreening af gravide kvinder. København: Statens Seruminstitut, 1988.
13. Nicolaides KH, Brizot ML, Snijders RMJ. Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy. Br J Obstet Gynaecol 1994; 101:782-6.
14. Källén B. Prenatal diagnosis of congenital malformations. The impact on birth defect monitoring and birth defect epidemiology. Int Clearinghouse for Birth Defects Monitoring Systems. London: (i trykken).
15. Jørgensen FS. Organisation af obstetrisk ultralyd i Danmark 1990. Ugeskr Læger 1992; 154: 2898-905.
16. Jørgensen FS. Ultralydundersøgelse af gravide kvinder i Danmark 1989-1990. Ugeskr Læger 1993; 155: 1627-32.
17. Merkatz IR Nitowsky HM, Macri JN, Johnson WJ. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984; 148: 886-94.
18. Tabor A, Larsen SO, Nielsen J, Nielsen J, Philip J, Pilgaard B et al. Screening for Down's syndrome using an iso-risk curve based on maternal age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987; 94: 636-42.
19. Nørgaard-Pedersen B, Larsen SO, Arends J, Svenstrup B, Tabor A. Maternal serum markers in screening for Down's syndrome. Clin Genet 1990; 37: 35-43.
20. Canick JA. Screening for Down syndrome using maternal serum alpha-fetoprotein, unconjugated estriol and HCG. J Clin Immunoassay 1990; 13: 30-3.
21. Wald NJ, Cuckle HS, Denserm JW, Nanchahal P, Royston T, Chard J et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988; 297: 883-7.
22. Wald NJ, Kennard A, Densem JW, Cuckle HS, Chard T. Butler L Antenatal maternal serum screening for Down's syndrome: results of a demonstration project BMJ 1992; 305: 391-4.
23. Goodburn SF, Yates JEW, Raggatt PR, Carr C, Ferguson-Smith ME, Kershaw AJ et al. Second trimester maternal serum screening using alphaphetoprotein, human chorionic gonadotropin, and unconjugated oestriol: experience of a regional programme. Prenat Diagn 1994; 14: 391-402.
24. Canick JA, Devereux NS Jr. Maternal serum screening for aneuploidy and open fetal defects. Obstet Clin North Am 1993; 20: 443-54.
25. Haddow JE, Palomaki GE, Knight GJ, Cunningham GC, Lustig LS, Boyd PA. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. N Engl J Med 1994; 330: 1114-8.
26. Jørgensen FS. Declining an alpha-fetoprotein test in pregnancy, why and who? Acta Obstet Gynecol Scand 1995; 74: 311.
27. Jørgensen FS. Attitudes to prenatal screening, diagnosis and research among pregnant women who accept or decline an alpha- fetoprotein test Prenat Diagn 1995; 15: 419-29.
28. Pauker SP, Pauker SG. Prenatal diagnosis - why is 35 a magic number? N Engl J Med 1994; 330: 1151-2.
29. Report of the RCOG Working Party on Biochemical Markers and the Detection of Down's Syndrome, London: The Royal College of Obstetricians and Gynaecologists, 1993.